colestipol

Summary

Summary: Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.

Top Publications

  1. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 2007;67:1383-92 pubmed
    ..In this article, we review the relationship between bile acid metabolism and glucose homeostasis, and present data demonstrating the utility of bile acid sequestrants in the management of diabetes...
  2. Weisweiler P. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia. Metabolism. 1989;38:271-4 pubmed
    ..activities were studied in 18 patients with familial hypercholesterolemia during 8-week treatment periods with colestipol (15 g/d), fenofibrate (0.25 g/d), and colestipol plus fenofibrate...
  3. Brown B, Bardsley J, Poulin D, Hillger L, Dowdy A, Maher V, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111-5 pubmed
    ..In an initial 12-month phase, regular niacin, 500 mg qid, lovastatin, 20 mg bid, and colestipol, 10 g/bid, were given with dose adjustment for lipid targets and side effects...
  4. Gaw A, Packard C, Lindsay G, Murray E, Griffin B, Caslake M, et al. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1996;16:236-49 pubmed
    The effects of colestipol therapy alone (20 g/d) or combined with simvastatin (20 mg/d) were examined in a group of eight male patients with primary moderate hypercholesterolemia (total cholesterol > or = 6...
  5. Benson G, Haynes C, Blanchard S, Ellis D. In vitro studies to investigate the reasons for the low potency of cholestyramine and colestipol. J Pharm Sci. 1993;82:80-6 pubmed
    The association rates, dissociation rates, and equilibrium binding of bile acids with cholestyramine and colestipol were measured under physiological conditions with the most abundant bile acids found in humans...
  6. Blankenhorn D, Azen S, Crawford D, Nessim S, Sanmarco M, Selzer R, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438-47 pubmed
    ..Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery...
  7. Spence J, Huff M, Heidenheim P, Viswanatha A, Munoz C, Lindsay R, et al. Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia. Ann Intern Med. 1995;123:493-9 pubmed
    To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated with colestipol and maintains or increases its efficacy in the treatment of hyperlipidemia...
  8. Cashin Hemphill L, Mack W, Pogoda J, Sanmarco M, Azen S, Blankenhorn D. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-7 pubmed
    ..Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects...
  9. Konzem S, Gray D, Kashyap M. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy. 1997;17:576-83 pubmed
    ..whether a formal, integrated pharmaceutical care plan can enhance patient acceptance and compliance with colestipol therapy and improve outcomes...

More Information

Publications95

  1. Blankenhorn D, Selzer R, Crawford D, Barth J, Liu C, Liu C, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-8 pubmed
    ..The Cholesterol Lowering Atherosclerosis Study, a coronary, cervical, and femoral angiographic trial of colestipol plus niacin, included a pilot study of standardized carotid ultrasound imaging.
  2. Mack W, Selzer R, Hodis H, Erickson J, Liu C, Liu C, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke. 1993;24:1779-83 pubmed
    ..has reported significant reduction of coronary artery disease and of carotid arterial intima-media thickness (IMT) at 2 and 4 years with colestipol/niacin therapy. We now report on treatment effects on carotid IMT at 6 months and 1 year.
  3. Schrott H, Stein E, Dujovne C, Davidson M, Goris G, Oliphant T, et al. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75:34-9 pubmed
    ..lipoprotein (LDL) cholesterol were randomly assigned to 4 different double-blind treatment regimens: placebo; colestipol 5 g and lovastatin 20 mg/day (C5 + L20); colestipol 10 g and lovastatin 20 mg/day (C10 + L20); and lovastatin 40 ..
  4. Insull W, Davidson M, Demke D, Dujovne C, Eckert S, Ginsberg D, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995;112:223-35 pubmed
    ..study was to investigate and compare the efficacy, safety, and patient acceptability of a new formulation of colestipol, colestipol tablets (T), with those of colestipol granules (G), in a randomized, double-blind, placebo-..
  5. Malloy M, Kane J, Kunitake S, Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987;107:616-23 pubmed
    To compare the effectiveness of the ternary-drug combination of colestipol, niacin, and lovastatin with binary combinations of those drugs in treating patients with familial hypercholesterolemia.
  6. Forland S, Feng Y, Cutler R. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol. 1990;30:29-32 pubmed
    b>Colestipol and gemfibrozil may be used in combination to lower serum cholesterol and triglycerides...
  7. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40 Suppl 1:S53-8 pubmed
    Interruption of the enterohepatic circulation of bile acids by cholestyramine or colestipol influences the hepatic metabolism of cholesterol in many ways...
  8. Nervi F, Marinovic I, Rigotti A, Ulloa N. Regulation of biliary cholesterol secretion. Functional relationship between the canalicular and sinusoidal cholesterol secretory pathways in the rat. J Clin Invest. 1988;82:1818-25 pubmed
    ..Diosgenin, fructose, and colestipol in the diet were used to, respectively, influence biliary cholesterol output, VLDL production and bile salt ..
  9. Piepho R. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000;86:35L-40L pubmed
    ..Niacin has few drug interactions and is a relatively inexpensive means of increasing HDL-C. A combination formulation that combines niacin plus a statin has shown promise in ongoing clinical trials. ..
  10. Zhao X, Phan B, Davis J, Isquith D, Dowdy A, Boltz S, et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. J Clin Lipidol. 2016;10:1091-7 pubmed publisher
    ..5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40-80 mg/d) and niacin from 2005 to ..
  11. Farmer J, Gotto A. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf. 1994;11:301-9 pubmed
    ..The major interaction involving probucol is a possible additive effect with drugs or clinical conditions that alter the prolongation of the QTc interval, increasing the potential for polymorphic ventricular tachycardia. ..
  12. O Neill F, Patel D, Knight B, Neuwirth C, Bourbon M, Soutar A, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2001;21:832-7 pubmed
    ..If so, statin responsiveness could be enhanced by reducing dietary cholesterol intake or inhibiting absorption. ..
  13. Stewart B, Brown B, Zhao X, Hillger L, Sniderman A, Dowdy A, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23:899-906 pubmed
    ..Such patients should be considered more likely, not less, to benefit from intensive lipid-lowering therapy. ..
  14. Potts J, Setness P. Elevated cholesterol levels. How to individualize treatment. Postgrad Med. 1990;88:233-9 pubmed
    ..An elevated total cholesterol level is only one of several important risk factors for coronary artery disease that must be confronted. ..
  15. Wirebaugh S, Shapiro M, McIntyre T, Whitney E. A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin. Pharmacotherapy. 1992;12:445-50 pubmed
    ..This retrospective data analysis suggests that the combination of gemfibrozil and lovastatin may be safe in patients with normal renal function when the dosage of lovastatin is limited and when CK and ALT levels are monitored carefully. ..
  16. Sun X, Patel D, Knight B, Soutar A. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study G. Atherosclerosis. 1998;136:175-85 pubmed
  17. Simonet W, Ness G. Transcriptional and posttranscriptional regulation of rat hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase by thyroid hormones. J Biol Chem. 1988;263:12448-53 pubmed
    ..Reductase mRNA decayed with a half-life of 2.5 h when mevinolin, a potent inhibitor of HMG-CoA reductase, and colestipol, a bile acid sequesterant, were removed from the diet of hypophysectomized rats...
  18. Cuthbert J, East C, Lipsky P. Normalization of LDL receptor function by lymphocytes of patients with heterozygous familial hypercholesterolemia after treatment with plasma cholesterol lowering agents. Am J Med Sci. 1989;298:152-60 pubmed
    ..These results provide direct evidence that therapy with lovastatin and a bile acid-binding resin can lead to increased expression of functional LDL receptors by lymphocytes in the majority (eight of 12) of patients with heterozygous FH. ..
  19. Day C. Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and colestipol hydrochloride in cholesterol fed SEA quail. Artery. 1990;17:281-8 pubmed
    The pharmacopolymer bile acid sequestrants cholestyramine and colestipol hydrochloride were mixed with a diet supplemented with 0.5% cholesterol at levels of 0.25%, 0.5%, and 1.0% for cholestyramine and 0.5% and 1...
  20. Rudling M. Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J Lipid Res. 1992;33:493-501 pubmed
    ..received established high fat diets, cholesterol-enriched diets, and a diet supplemented with mevinolin and colestipol. One hundred nineteen animals were investigated in six separate experiments...
  21. Lapuerta P, Azen S, Labree L. Use of neural networks in predicting the risk of coronary artery disease. Comput Biomed Res. 1995;28:38-52 pubmed
    ..005). The network design provided an effective approach to predicting outcomes from a clinical trial with variable follow-up times. ..
  22. Feingold K, Pollock A, Moser A, Shigenaga J, Grunfeld C. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res. 1995;36:1474-82 pubmed
    ..In both cholesterol- and colestipol-fed animals, LPS increased HMG-CoA reductase mRNA levels while either decreasing or causing minimal increases in ..
  23. Bilheimer D, Grundy S, Brown M, Goldstein J. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. Atheroscler Suppl. 2004;5:61-5 pubmed
  24. Azen S, Cashin Hemphill L, Pogoda J, Mack W, Sanmarco M, Wickham E, et al. Evaluation of human panelists in assessing coronary atherosclerosis. Arterioscler Thromb. 1991;11:385-94 pubmed
    ..Study, a randomized, angiographic clinical trial, has demonstrated the beneficial effect of niacin/colestipol therapy on coronary and femoral atherosclerosis...
  25. Schulman K, Kinosian B, Jacobson T, Glick H, Willian M, Koffer H, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA. 1990;264:3025-33 pubmed
    ..Agents modeled were cholestyramine, colestipol, gemfibrozil, lovastatin, niacin, and probucol. Pharmacologic effectiveness was estimated from reported studies...
  26. Blankenhorn D, Alaupovic P, Wickham E, Chin H, Azen S. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81:470-6 pubmed
    ..angiographic change in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled trial of colestipol plus niacin therapy in men with previous coronary bypass surgery...
  27. Hagag P, Nissenbaum H, Weiss M. Role of colestipol in the treatment of hyperthyroidism. J Endocrinol Invest. 1998;21:725-31 pubmed
    ..We, therefore, evaluated the effect of colestipol-hydrochloride administration on clinical and biochemical indices of patients with hyperthyroidism...
  28. Polin D, Underwood M, Lehning E, Olson B, Bursian S. Enhanced withdrawal of polychlorinated biphenyls: a comparison of colestipol, mineral oil, propylene glycol, and petroleum jelly with or without restricted feeding. Poult Sci. 1989;68:885-90 pubmed
    ..to hasten the withdrawal of PCB with either mineral oil (MO), petroleum jelly (PJ), propylene glycol (PG), or colestipol (CO) at 5% of the diet, or at 10% of the diet when restricted to 50% of control intake (50% FR)...
  29. Valek J, Jirkovska A, Grafnetter D. [Small doses of the resin Colestid in the treatment of hyperlipoproteinemia]. Cas Lek Cesk. 1991;130:172-6 pubmed
  30. Brown A, Bakker Arkema R, Yellen L, Henley R, Guthrie R, Campbell C, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32:665-72 pubmed
    ..at week 54 with the last available visit carried forward were atorvastatin 20 mg/day, fluvastatin 40 mg/day + colestipol 20 g/day, lovastatin 80 mg/day, simvastatin 40 mg/day. A significantly greater number (p < 0...
  31. McCrindle B, Helden E, Cullen Dean G, Conner W. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res. 2002;51:715-21 pubmed
    We sought to determine whether a low-dose combination of a bile acid-binding resin (colestipol) with an hydroxymethylglutaryl CoA reductase inhibitor (pravastatin) would result in improved acceptability, compliance, and effectiveness in ..
  32. Rossi S, Wayne M, Smith R, Wright C, Andreadis N, Hofmann A. Effect of the bile-acid sequestrant colestipol on postprandial serum bile-acid concentration: evaluation by bioluminescent enzymic analysis. Aliment Pharmacol Ther. 1989;3:41-6 pubmed
    ..hypercholesterolaemic subjects during the ingestion of three standard meals, with or without the addition of 5 g colestipol granules administered 30 min before each meal...
  33. El Sayed Y, al Meshal M, Al Angary A, Lutfi K, Gouda M. The effect of colestipol and cholestyramine on the systemic clearance of intravenous ibuprofen in rabbits. J Pharm Pharmacol. 1994;46:73-5 pubmed
    The effect of oral administration of the non-absorbable anion-exchange resins cholestyramine and colestipol on the systemic clearance and other pharmacokinetic parameters of intravenously administered ibuprofen (25 mg kg-1) was studied in ..
  34. Sirmans S, Beck J, Banh H, Freeman D. Colestipol-induced hepatotoxicity. Pharmacotherapy. 2001;21:513-6 pubmed
    A 65-year-old man with type IIa dyslipidemia who received flavored colestipol granules 2 scoops/day for 3 months developed asymptomatic hepatotoxicity. Several of his liver enzymes were elevated 10 times the upper limit of normal...
  35. Desager J, Horsmans Y, Harvengt C. Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. J Clin Pharmacol. 1991;31:537-42 pubmed
    ..familial hypercholesterolemia (FH), the effects of simvastatin (S) 20 mg/d, 40 mg/d, and 40 mg/d plus low-dose colestipol (10 g/d) on plasma lipids, plasma lipoproteins, and plasma lecithin: cholesterol acyltransferase (LCAT) activity ..
  36. East C, Bilheimer D, Grundy S. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988;109:25-32 pubmed
    To compare the efficacy of gemfibrozil and colestipol with gemfibrozil and lovastatin in patients with familial combined hyperlipidemia. A prospective, randomized trial. An outpatient clinical research center in a tertiary care center...
  37. Ness G, Pendleton L, McCreery M. In situ determination of the functional size of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase by radiation inactivation analysis. Biochim Biophys Acta. 1988;953:361-4 pubmed
    ..1.1.34) from rats fed a normal diet. Feeding a diet containing mevinolin and colestipol, which causes a marked increase in enzyme activity, resulted in a reduction of the target size to 120 kDa...
  38. al Balla S, El Sayed Y, al Meshal M, Gouda M. The effects of cholestyramine and colestipol on the absorption of diclofenac in man. Int J Clin Pharmacol Ther. 1994;32:441-5 pubmed
    The effect of oral administration of the non-absorbable anion-exchange resins cholestyramine and colestipol hydrochloride on the absorption of diclofenac in man was studied. Adsorption studies in vitro were also performed...
  39. Zambon A, Deeb S, Brown B, Hokanson J, Brunzell J. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation. 2001;103:792-8 pubmed
    ..This study identifies a gene polymorphism that strongly influences the lipid and clinical response to lipid-lowering drugs. ..
  40. Ast M, Frishman W. Bile acid sequestrants. J Clin Pharmacol. 1990;30:99-106 pubmed
    The bile acid sequestrants, cholestyramine and colestipol, are the drugs of choice for the treatment of patients with hypercholesterolemia caused by increases in LDL-cholesterol levels without concurrent hypertriglyceridemia (type IIA and ..
  41. Xydakis A, Guyton J, Chiou P, Stein J, Jones P, Ballantyne C. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004;94:795-7 pubmed
    ..03), without significantly changing high-density lipoprotein cholesterol, and the combination was well tolerated...
  42. Azen S, Mack W, Cashin Hemphill L, Labree L, Shircore A, Selzer R, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996;93:34-41 pubmed
    ..Because no single method or measure for a coronary angiographic end point is uniformly accepted as optimal, the utility and validity of surrogate end points for predicting clinical coronary events remain unsettled...
  43. Day C. Anti-atherosclerotic activity of colestipol hydrochloride in SEA quail. Artery. 1990;17:119-26 pubmed
    ..ten animals was fed the atherogenic diet for eight weeks, and another group was fed the same diet containing 2% colestipol hydrochloride for the same length of time...
  44. Luhman C, Miller B, Beitz D. The effect of feeding lovastatin and colestipol on production and cholesterol content of eggs. Poult Sci. 1990;69:852-5 pubmed
    The purpose of the present study was to determine whether feeding lovastatin or colestipol, or both, to laying hens would decrease the concentration of cholesterol in eggs...
  45. Mack W, Labree L, Liu C, Selzer R, Hodis H. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis. 2000;150:371-9 pubmed
    ..Lowering Atherosclerosis Study, current nonsmoking men with coronary artery disease were randomized to colestipol-niacin or placebo...
  46. Faulkner M, Wadibia E, Lucas B, Hilleman D. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy. 2000;20:410-6 pubmed
    ..All patients received lovastatin 20 mg/day and colestipol 5 g twice/day. Weekly telephone contact was made with each patient for 12 weeks...
  47. Bilicki C, White J, Hem S, Borin M. Effect of anions on adsorption of bile salts by colestipol hydrochloride. Pharm Res. 1989;6:794-7 pubmed
    The Langmuir affinity constant and adsorptive capacity for the adsorption of citrate anion or cholate anion by colestipol hydrochloride at pH 7.5, 37 degrees C, were similar...
  48. Danley T, St Anna L. Clinical inquiry. Postcholecystectomy diarrhea: what relieves it?. J Fam Pract. 2011;60:632c-d pubmed
    A trial of a bile acid binder such as cholestyramine or colestipol may benefit patients with postcholecystectomy diarrhea.
  49. Thompson G, Maher V, Matthews S, Kitano Y, Neuwirth C, Shortt M, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811-6 pubmed
    ..LDL apheresis fortnightly (with disposable dextran sulphate/cellulose columns) plus simvastatin 40 mg daily, or colestipol 20 g plus simvastatin 40 mg daily. Quantitative coronary angiography was repeated after a mean of 2...
  50. Day C. Hypocholesterolemic activity of colestipol hydrochloride in SEA quail. Artery. 1989;17:49-59 pubmed
    ..5% cholesterol for a period of one week. Colestipol hydrochloride was mixed with the diet at levels of 0.5% and 1.0%...
  51. Paterson R, Paat J, Steele G, Hathaway S, Wong J. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. South Med J. 1994;87:236-42 pubmed
    ..These studies clearly support intensive lipid modulation in patients with established coronary disease...
  52. Ness G, Gertz K, Holland R. Regulation of hepatic lanosterol 14 alpha-demethylase gene expression by dietary cholesterol and cholesterol-lowering agents. Arch Biochem Biophys. 2001;395:233-8 pubmed
    ..02%, raised 14DM mRNA and protein levels 2- to 3-fold. Addition of 2% Colestipol, a bile acid binding resin, to the chow diet caused smaller increases...
  53. Shimomura I, Shimano H, Horton J, Goldstein J, Brown M. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest. 1997;99:838-45 pubmed
    ..2-fold), and the 1c transcript remained virtually undetectable. We conclude that the SREBP-1a and 1c transcripts are controlled independently by regulatory regions that respond differentially to organ-specific and metabolic factors...
  54. Hansen D, Michaelsen K, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Paediatr. 1992;81:1023-5 pubmed
    ..We examined the growth of 30 children with familial hypercholesterolemia, some of whom were also treated with colestipol, a bile acid-binding resin. The median duration of treatment was 8.5 years in 13 patients on diet only, and 5...
  55. Mol M, Stuyt P, Demacker P, Stalenhoef A. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. Neth J Med. 1990;36:182-90 pubmed
    ..Side effects were limited to slight increases in alanine aminotransferase and creatine phosphokinase in some patients. Simvastatin appears to be an important asset in the treatment of hypercholesterolaemia...
  56. Twisk J, Hoekman M, Mager W, Moorman A, de Boer P, Scheja L, et al. Heterogeneous expression of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase genes in the rat liver lobulus. J Clin Invest. 1995;95:1235-43 pubmed
    ..Opposite lobular localization of cholesterol and bile acid synthesis provides an alternative view to interregulation of these metabolic pathways...
  57. Thomas E, Cudahy M, Spilman C, Dinh D, Watkins T, Vidmar T. Cholesterol lowering bile acid binding agents: novel lipophilic polyamines. J Med Chem. 1992;35:1233-45 pubmed
    ..3HCl) and N,N-bis[2-(cyclododecylmethylamino)ethyl]-N',N'-dimethyl-1,2-ethan ediamine (23), are 29 and 24 times more potent than colestipol hydrochloride, respectively, for lowering animal serum cholesterol levels.
  58. Horsmans Y, Desager J, Harvengt C. Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol. 1990;67:336-9 pubmed
  59. Friedman H, Greenblatt D, LeDuc B. Impaired absorption of tetracycline by colestipol is not reversed by orange juice. J Clin Pharmacol. 1989;29:748-51 pubmed
    ..received a 500 mg oral dose of tetracycline hydrochloride in three trials: A: With 180 ml water; B: With 30 gm colestipol in 180 ml water; C: With 30 gm colestipol in 180 ml orange juice...
  60. Rosenson R, Baker A, Chow M, Hay R. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology. 1990;98:1351-7 pubmed
    ..3. The cutaneous xanthomata were markedly diminished 1 wk following plasma exchange. Despite therapy with colestipol (30 g/d), the hyperviscosity syndrome developed 147 days later...
  61. Iversen S, Davidson D, Davidson C. The acceptability of resin therapy to patients attending a hospital lipid clinic. Br J Clin Pharmacol. 1995;40:92-4 pubmed
    Low dose cholestyramine ('Questran A') and colestipol ('Colestid Orange') were compared in a blinded two period crossover study of 55 patients attending a hospital lipid clinic...
  62. Zambon A, Hokanson J, Brown B, Brunzell J. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99:1959-64 pubmed
    ..This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy...
  63. Neuvonen P, Kivistö K, Hirvisalo E. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol. 1988;25:229-33 pubmed
    ..2. In a cross-over study consisting of four phases, single doses of colestipol hydrochloride (10 g), cholestyramine (8 g), activated charcoal (8 g) or water only were given to six healthy ..
  64. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature. Pharmacoeconomics. 1992;2:34-42 pubmed
    ..that met all criteria for inclusion in our review, including 3 of bile-acid sequestrants (cholestyramine, colestipol), 2 of HMG-CoA reductase inhibitor (lovastatin), and 4 that considered both an HMG-CoA reductase inhibitor (..
  65. Fleishaker J, Rossi S, Smith R, Welshman I, Daei F, Angellotti M, et al. The effect of colestipol dose on postprandial serum bile acid concentration: assessment by an enzymic bioluminescence procedure. Aliment Pharmacol Ther. 1990;4:623-33 pubmed
    A dose-response study was performed with three doses of colestipol, using postprandial serum bile acid levels to assess bile acid sequestering activity in 40 volunteers with asymptomatic hyperlipidaemia...
  66. Zambon A, Brown B, Hokanson J, Motulsky A, Brunzell J. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy. J Intern Med. 2006;259:401-9 pubmed
  67. Ceska R, Sobra J, Toschnerová H, Traurig J. [Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia]. Cas Lek Cesk. 1992;131:183-5 pubmed
    ..assembled with the treatment of 14 heterozygotes with familial hypercholesterolaemia by a combination of colestipol (Colestid Upjohn, Belgium) with gemfibrosil (Loped Parke-Davis, USA), 15 g and 1200 mg resp. per day...
  68. Ung K, Gillberg R, Kilander A, Abrahamsson H. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut. 2000;46:170-5 pubmed
    ..In a retrospective study bile acid malabsorption was observed in patients with collagenous colitis...
  69. Lyons D, Webster J, Fowler G, Petrie J. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol. 1994;37:59-62 pubmed
    1. Bile acid sequestrants such as colestipol are effective lipid lowering agents but have a poor reputation for tolerability particularly when administered at the originally recommended doses...
  70. Ugele B, Kempen H, Kempen J, Gebhardt R, Meijer P, Burger H, et al. Heterogeneity of rat liver parenchyma in cholesterol 7 alpha-hydroxylase and bile acid synthesis. Biochem J. 1991;276 ( Pt 1):73-7 pubmed
    ..Furthermore, the opposite acinar localization of cholesterol and bile acid biosynthesis provides an interesting alternative to current views of the regulation of their metabolic pathways...
  71. Farmer J, Gotto A. Choosing the right lipid-regulating agent. A guide to selection. Drugs. 1996;52:649-61 pubmed
    ..When used correctly, lipid-regulating drug therapy is highly effective in the treatment of a variety of dyslipidaemias...
  72. Turner S, Jungbluth G, Knuth D. Effect of concomitant colestipol hydrochloride administration on the bioavailability of diltiazem from immediate- and sustained-release formulations. Biopharm Drug Dispos. 2002;23:369-77 pubmed
    Effects of concomitant colestipol administration on plasma concentrations of diltiazem and desacetyldiltiazem from immediate-release (IR) and sustained-release (SR) formulations were assessed in two studies...
  73. Blankenhorn D, Selzer R, Mack W, Crawford D, Pogoda J, Lee P, et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation. 1992;86:1701-9 pubmed
    The Cholesterol Lowering Atherosclerosis Study has demonstrated beneficial effect of colestipol/niacin on coronary atherosclerosis using a panel-determined global coronary change score...
  74. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child. 1996;74:157-60 pubmed
    The effects of orange flavoured colestipol granules, 10 g/day, in 37 boys and 29 girls aged 10-16 years with familial hypercholesterolaemia were examined first in an eight week double blind, placebo controlled protocol, then in open ..
  75. Cortner J, Coates P, Liacouras C, Jarvik G. Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. J Pediatr. 1993;123:177-84 pubmed
    ..13 mmol/L (160 mg/dl) after dietary modification...
  76. Houlston R, Quiney J, Watts G, Lewis B. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia. J R Soc Med. 1988;81:274-6 pubmed
    ..In type III, plasma cholesterol was reduced by 40% and plasma triglyceride by 70%, while high-density lipoprotein cholesterol increased by 45%. In none of the patients studied did clinical or biochemical side effects occur...
  77. Stein E. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis. 1989;9:I145-51 pubmed
    ..In a number of these subjects, absolute lipid levels were approaching optimal levels. In the three Ho FH subjects, the response to HMG CoA reductase inhibitors was variable but generally poor.(ABSTRACT TRUNCATED AT 250 WORDS)..
  78. van Doormaal J, Smit N, Koopman B, van der Molen J, Wolthers B, Doorenbos H. Hydroxycholesterols in serum from hypercholesterolaemic patients with and without bile acid sequestrant therapy. Clin Chim Acta. 1989;181:273-9 pubmed
    ..and high normal to elevated 26-hydroxycholesterol levels, a group of 5 male and 9 female patients, using colestipol had higher 7 alpha-hydroxycholesterol without overlap, and higher 7 beta-hydroxycholesterol levels, but similar ..
  79. Mack W, Xiang M, Selzer R, Hodis H. Serial quantitative coronary angiography and coronary events. Am Heart J. 2000;139:993-9 pubmed
    ..Although assessment of progression of atherosclerosis by quantitative coronary angiography (QCA) is used as a surrogate for coronary events, no validation study has compared the several QCA measures used...
  80. Hodis H. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol. 1995;25 Suppl 4:S25-31 pubmed
    ..Together, CLAS and MARS data indicate that the spectrum from very early lesions confined to the arterial wall to established lesions late in the atherosclerotic process can be reversed with lipid-lowering therapy...
  81. Steinmetz K. Colesevelam hydrochloride. Am J Health Syst Pharm. 2002;59:932-9 pubmed
    ..Unlike cholestyramine and colestipol, colesevelam appears to reduce LDL cholesterol in a dose-dependent manner...
  82. Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis. 2002;164:381-2 pubmed
  83. Lind S, Rudling M, Ericsson S, Olivecrona H, Eriksson M, Borgström B, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol. 2004;24:349-56 pubmed
    ..We characterized the influence of GH treatment on plasma LDL clearance in normal humans and investigated the relative role of LDL receptor (LDLR) activity and stimulation of bile acid synthesis in subjects with different LDLR expression...
  84. Mack W, Selzer R, Pogoda J, Lee P, Shircore A, Azen S, et al. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Arterioscler Thromb. 1992;12:348-56 pubmed
    ..Atherosclerosis Study, a randomized angiographic clinical trial, demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis...
  85. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr. 1996;85:1080-2 pubmed
    The objective of this study was to examine palatability and side effects of the new tablet formulation of colestipol. A clinical series of 23 boys and 4 girls aged 10-16 years with heterozygous familial hypercholesterolaemia were given 2-..
  86. Silva V, Oliveira L, Gonçalves P. Alteration of aluminium inhibition of synaptosomal (Na(+)/K(+))ATPase by colestipol administration. J Inorg Biochem. 2013;128:208-14 pubmed publisher
    ..Adult male Wistar rats were submitted to chronic dietary AlCl3 exposure (0.03 g/day of AlCl3) and/or to colestipol, a hypolidaemic drug (0.31 g/day) during 4 months...